Litcius/Paper detail

Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry

Heiner Zimmermann, Mirko Nitsche, Christiane Pott, Petra Reinke, Nina Babel, Robert Michael Hermann, Ingeborg A. Hauser, D Hahn, Matthias Ritgen, Claudia Pietschmann, Wolfgang Hiddemann, Ioannis Anagnostopoulos, Ralf Ulrich Trappe, for the German PTLD Study Group and German Lymphoma Alliance

2021Annals of Hematology18 citationsDOI

Topics & Concepts

ImmunosuppressionMedicineRituximabHematologyCentral nervous systemInternal medicineLymphoproliferative disordersPost-transplant lymphoproliferative disorderOncologyImmunologyLymphomaCNS Lymphoma Diagnosis and TreatmentViral-associated cancers and disordersPolyomavirus and related diseases
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry | Litcius